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Thesis Statement
One needs only to turn on the television to see the impact head trauma has had on us as a
society. We see commercials for veterans coming home whom have suffered TBI’s due to
injuries in the line of battle. We see athletes suffering from the effects of neurodegenerative
diseases such as chronic traumatic encephalopathy (CTE). Most of these symptoms are hidden,
making it easy to sweep the problem under the rug, so to speak. As of late, we are hearing of
major sports leagues such as the National Hockey League (NHL), National Football League
(NFL), Major League Baseball (MLB), some mixed martial arts companies such as UFC, as well
as professional wrestling companies such as World Wrestling Entertainment (WWE) taking the
lead in prevention of head trauma. The past two years in particular we have seen more
suspensions and fines in the NFL and NHL for intentional hits to the head which can cause a
TBI. It is more difficult to take action against strong blows to the body, which can also cause a
TBI, due to the nature of these sports, but we have a starting point with these major
organizations. This is a problem we must address, and we must address it early. Failure to do so
will only result in more suffering for those whom have suffered a brain injury (or in some
instances multiple brain injuries) as well as those around them. Due to the changes in the brain,
we do see emotional problems arise which is where we have seen irrational acts such as domestic
violence, murders and suicides. If we do not address this problem, these acts will continue and it
will become a vicious circle.
In my thesis, I plan to explain what a traumatic brain injury (TBI) is, as well as second
impact syndrome (SIS), its symptoms, and the role age, gender and genetics play in not only
suffering a TBI but the effects these factors play in recovery from the injury. I also plan on
exploring what a neurodegenerative disease is and the role TBI’s play in these diseases. I will
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explore different treatment options, including the latest information on treatment that is in its
early testing phases such as focused ultrasound, which has suggested a non-pharmaceutical way
to treat neurodegenerative disease and possibly break up the plaques that accompany these
diseases. Finally I will look at prevention of head trauma and what the future holds for research
in the field of head trauma and neurodegenerative disease.
Through my thesis, I plan on showing that future research is needed as this is a rapidly
evolving field. We are continually finding out new information on how the brain reacts to trauma
both immediately following an injury as well as long term. Along with this we also are
discovering new treatment methods. My hope would be that we could discover more nonpharmaceutical methods of treatment of TBI’s in both the short term and long term. I personally
have suffered numerous TBI’s from wrestling professionally and suffer through many of the
symptoms I will discuss. If my thesis helps even one other person not experience what I am now
suffering from, then my thesis would be a success.
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Introduction
Over the past several years we have seen a link between concussions, otherwise known as
traumatic brain injury (TBI), emotional difficulties and suicide (Omalu, Bailes, Hammers, &
Fitzsimmons, 2010). We also have seen an increase in suicides in both active military as well as
veterans over the past several years. Suicides in the US Army reached the highest levels in 28
years in 2008 (Kuehn, 2009). TBI is common for both contact sport athletes and military
members returning from battle, where we see “much of the initial controlled data on mTBI and
concussions was gleaned from athletes who were at high risk for mild head trauma. With the
multiple combat tours and the nature of warfare in Iraq and Afghanistan that are putting service
members at risk for multiple concussive injuries, the lessons learned from the sports concussion
literature are being applied to the military. While there are differences when TBIs occur in the
combat setting, there are also similarities” (Kelly, Amerson, & Bath, 2012, p. 4). This has helped
place more emphasis on head injuries. While we cannot definitively say there is a direct link
between the two, there is something that many members of both of these demographics have in
common. The tie that binds these groups, as mentioned above, would be TBI’s. While I have
discussed TBIs in the military, most of my research will focus on athletes. While many military
members have suffered TBI’s, they also suffer from Post-Traumatic Stress Disorder (PTSD) as
well which has psychological symptoms that could skew our view of the symptoms suffered by
those suffering from TBI’s. Despite this fact, we can draw some correlation between the two. I
plan to explore the causes, symptoms and prevention of TBI’s as well as a correlation between
TBI’s and neurological diseases, including the cognitive and neurological deficits that
accompany them.
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TBI and Second Impact Syndrome
What exactly is a TBI? In a 2011 study by Schatz, Moder, Covassin, and Karpf (2011)
they state that due to the increasing number of sports related TBI’s, the Centers for Disease
Control and Prevention has identified concussion (TBI) from sports an “epidemic” in the United
States. The Centers for Disease Control and Prevention sums it up quite nicely by saying “a TBI
is caused by a bump, blow, or jolt to the head that can change the way your brain normally
works. Concussions can also occur from a fall or a blow to the body that causes the head and
brain to move quickly back and forth” (Centers for Disease Control and Prevention, 2014). It is
important to realize that not only blows to the head, but blows to the body can cause a TBI.
“Animal studies were revealing neuropathological/histological changes in the brain stems of
primates when subjected to acceleration, deceleration, rotational injuries, or mild traumatic brain
injuries (mTBIs)” (Kelly, Amerson, & Bath, 2012, p. 1). There is no doubt that TBI’s are a
serious problem.
During an initial TBI we see brain swelling, but we also see a disruption of
autoregulation of cerebral blood flow (Wetjen, Pichelmann, & Atkinson, 2010). In a study by
Wetjen, Pichelmann, and Atkinson (2010) it was noted that during the initial head trauma, we see
“induced cerebral autoregulation failure, with simultaneous catecholamine-induced marked
blood pressure elevation” (Wetjen, Pichelmann, & Atkinson, 2010, p. 533) leading to rapid brain
swelling. It stands to reason that it is “highly probable that the same events occur” (Wetjen et al.,
2010, p. 553) in what is called second impact syndrome (SIS). “Cerebral autoregulation is best
described as the “tone” the arterial tree assumes to either uniformly dilate or constrict to keep
cerebral blood flow constant under normal conditions”(Wetjen et al., 2010, p. 553). Wetjen,
Pichelmann, and Atkinson (2010) has found that this disruption in cerebral autoregulation occurs
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in a linear fashion. In other words, the more serious the head trauma, the more serious the
disruption to cerebral autoregulation will be. The release of catecholamine and its effects “occurs
rapidly, within seconds of the head injury” (Wetjen et al., 2010, p. 554). We see a “rapid
elevation in blood pressure” (Wetjen et al., 2010, p. 554) and heart rate. It has also been
documented that there is a release of epinephrine and norepinephrine in cases of severe head
trauma, which can have impacts on heart rate and blood pressure. It is suspected that these
releases are linear as well (Wetjen et al., 2010, p. 554). It is this rapid swelling, release of
catecholamine, increased blood pressure and heart rate, as well as the increase in epinephrine and
norepinephrine that can be fatal. When a person suffers an initial TBI and then suffers a second
TBI before completely healing from the initial injury, which is SIS, we see these effects occur
again, increasing the chances of the injury being fatal.
Key to understanding exactly what a TBI is, is to understand the symptoms of a TBI. The
“most widely used clinical TBI severity classification” (Bruns and Hauser, 2003, p. 8) system
used is the Glasgow Coma Scale. The Mayo Clinic has some key symptoms on their website for
both mild to moderate/severe TBI’s. With mild TBI’s we may see physical symptoms that range
from loss of consciousness for a few seconds up to a few minutes. A loss of consciousness is not
required for a diagnosis of a TBI though, as we do see some patients who have no loss of
consciousness, but they may be in a state where they are dazed, confused or disoriented. Often
times those who have suffered a mild TBI also will experience headaches, nausea or vomiting,
fatigue or drowsiness, difficulty sleeping or sleeping more than usual, as well as dizziness or loss
of balance. There are also sensory symptoms which accompany a mild TBI such as sensitivity to
light or sound. Often the patient may have blurred vision, ringing in the ears, a bad taste in the
mouth or changes in the ability to smell. There also may be cognitive or mental symptoms which
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will be explored in greater detail later. This may include memory or concentration problems,
mood changes or mood swings, as well as feeling depressed or anxious (The Mayo Clinic, 2014).
Moderate to severe TBI’s include all of the symptoms of mild TBI’s as well as additional
symptoms that may appear in the hours or days following the initial TBI. Physical symptoms
may include loss of consciousness from several minutes to hours, persistent headache or a
headache that worsens with time, repeated vomiting or nausea, convulsions or seizures, dilation
of one or both pupils of the eyes, and clear fluid draining from the nose or ears. We also may see
an inability to awaken from sleep, loss of coordination, as well as weakness or numbness in
fingers and toes. There are also cognitive or mental symptoms which include profound confusion
and slurred speech. Agitation, combativeness or other unusual behavior has also been seen in
those whom have suffered a moderate to severe TBI. In a severe injury, it is possible the patient
may slip into a coma and other disorders of consciousness (The Mayo Clinic, 2014).
The role of age and/or gender in the outcome of a TBI
Does age play a role in the outcome of a TBI?
There is limited information on the impact of TBI on pediatric patients. There is growing
concern regarding TBI’s and the youth whom play contact sports. Past research has estimated a
rate of at least a single TBI amongst high school athletes to be as high as “63% of a sample of
223 high school students” (Schatz, Moser, Covassin, & Karpf, 2011, p. 1563). And much like in
“adults, high school and college athletes have been shown to increase their likelihood of
sustaining a second concussion after the first” (Schatz, Moser, Covassin, & Karpf, 2011, p.
1563). Furthermore, “high school athletes who had sustained 3 or more concussions were more
likely to experience loss of consciousness with future concussions” (Schatz, Moser, Covassin, &
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Karpf, 2011, p. 1563). To add to this, otherwise “healthy high school students with a history of 2
or more concussions exhibited poorer performance on cognitive testing than healthy students
with a history of 1 or no concussion” (Schatz, Moser, Covassin, & Karpf, 2011, p. 1563). There
is significant evidence that “high school athletes with a history of 2 or more concussions
endorsed higher ratings on headache, balance problems and dizziness…high school athletes with
a history of 2 or more concussions endorsed higher ratings on nausea and fatigue” (Schatz,
Moser, Covassin, & Karpf, 2011, p. 1564) when compared with athletes whom suffered one or
no TBI’s. Unfortunately Schatz, Moser, Covassin and Karpf’s (2010) study was unable to draw a
conclusion whether athletes were experiencing enduring postconcussion symptoms or rather,
were more sensitive to physical, cognitive, and emotional fluctuations. It also is important to
point out that the results of Schatz, Moser, Covassin, and Karpf’s (2010) study were selfreported. Statistically, you stand a higher chance of bias in self-reported surveys because you are
relying on the subject reporting their symptoms. Due to each person being different, it is possible
that there may be inconsistency with the results. (Schatz, Moser, Covassin, & Karpf, 2011, p.
1566).
Meehan, Taylor and Proctor (2011) found that many student athletes do not seek
emergency medical attention for a TBI. It is interesting to note that the “assessment and
management of pediatric concussion is further complicated by the lack of injury reporting. In a
1983 study of football players in Minnesota high schools, 29% of athletes who sustained a
concussion were not examined by anyone at all. Only 22% were examined by medical personnel.
The remainder were attended to by a coach, parent, or teammate” (Meehan, Taylor, & Proctor,
2011, p. 3). One only needs to see this data to see how this can be a serious issue. This is a very
important factor in regards to TBI care for young adults. It is important to realize that the
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biomechanics of concussive injury differs between adult and pediatric patients” (Meehan,
Taylor, & Proctor, 2011, p. 2). There is a difference in the “relative size of the head compared to
the rest of the body, brain water content, vasculature, degree of myelination, and shape of the
skull account for the biomechanical differences” (Meehan, Taylor, & Proctor, 2011, p. 2). TBIs
are “caused primarily by a rotational acceleration of the brain” (Meehan, Taylor, & Proctor,
2011, p. 2). It also has been found that “as the neck muscles strengthen…this, in turn, reduces the
resultant acceleration for a given force” (Meehan, Taylor, & Proctor, 2011, p. 2). There are two
hypotheses in regards to this particular factor. Some believe the reduced muscle strength in the
neck may put “younger athletes… at increased risk for concussion when hit with the same
magnitude of force” (Meehan, Taylor, & Proctor, 2011, p. 2). Other researchers have
hypothesized that the fact that younger athletes have less muscle strength in their neck may
actually result in “less force delivered by the striking athlete at the time of injury, thereby
decreasing the risk of injury” (Meehan, Taylor, & Proctor, 2011, p. 2). A counter to this
hypothesis presented in Meehan, Taylor, and Proctor’s (2011) study is the fact that
“biomechanicians have demonstrated that greater force is required to cause similar concussive
injury to smaller brains than in larger brains with greater mass” (Meehan, Taylor, & Proctor,
2011, p. 2). In other words, children showing symptoms of a TBI may have sustained a blow
with greater force than an adult. The suggestion here is that the weaker neck muscles and larger
head may play a more important role in sustaining a TBI than the overall smaller size of the
athlete due to weaker forces being disproportionately applied to the brain (Meehan, Taylor, &
Proctor, 2011, p. 2).
Meehan, Taylor and Proctor (2011) state that “pediatric and adult brains are in different
phases of development, with the child’s brain growing and needing to acquire high volumes of
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new learning at a much faster pace. The pathophysiological response to TBI also differs between
the mature and developing brain” (Meehan, Taylor, & Proctor, 2011, p. 2). Meehan, Taylor and
Proctor (2011) state that children younger than three years of age were less likely to lose
consciousness, where children three to nine years of age were more likely to lose consciousness,
as well as were more prone to become comatose. Children three to nine years of age also
experienced less subdural hemorrhages while having more significant cerebral edema. Children
nine years and older who sustain a TBI display symptoms more in line with adults. Due to the
“age dependent injury patterns” (Meehan, Taylor, & Proctor, 2011, p. 2) further investigation
“into the possible differences in concussive brain injury between patients of varying ages”
(Meehan, Taylor, & Proctor, 2011, p. 2) is warranted. For example, “diffuse brain swelling after
TBI is more common in pediatric patients and results from mechanisms different from that of
adults” (Meehan, Taylor, & Proctor, 2011, p. 3). Meehan, Taylor and Proctor state that the exact
reason for this is unknown but it is suspected that differences in brain water content,
dopaminergic activity, vascular response to injury, glutamate receptor expression, and expression
of aquaporin 4 by microglia may play a role (Meehan, Taylor, & Proctor, 2011, p. 3).
Recovery time for a TBI can vary, but Meehan, Taylor and Proctor (2011) suggest that
younger athletes require a longer recovery time, which may possibly be related to age-dependent
brain physiology. The “underdeveloped or developing skills are presumed to be particularly
vulnerable” (Meehan, Taylor, & Proctor, 2011, p. 6). It has been suggested that “early insult may
have a significant impact on later development” (Meehan, Taylor, & Proctor, 2011, p. 6). There
is “evidence that concussive injuries sustained early in life may have minimal effect on already
established cognitive skills but may significantly delay the development of future skills”
(Meehan, Taylor, & Proctor, 2011, p. 6). We can see how this would have much more serious
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ramifications on a younger brain as opposed to an adult’s brain (Meehan, Taylor, & Proctor,
2011).
Does gender play a role in the outcome of a TBI?
Groswasser, Cohen, and Keren (1998) conducted a study to determine what, if any,
gender differences there may be in the outcome of severe TBI. Like many studies, they could not
inflict a TBI on someone for ethical reasons, so they determined the severity of the concussion
by looking at the duration of unconsciousness and matched this time frame up for both male and
female subjects. The predicted outcome after participation in an in-patient rehabilitation program
was determined by the subject’s work capacity. This study was one of the first to take an in depth
look at gender differences, largely due to the fact that previous TBI patients were primarily male,
outnumbering female patients three to one. This made it difficult to obtain a large enough sample
size of female subjects to provide a reliable statistical analysis. Even in this particular study, 262
subjects were male and 72 subjects were female, which follows the three to one ratio, but
researchers were able to obtain enough data to show statistical significance in regards to gender
differences (Groswasser, Cohen, & Keren, 1998, p. 805).
If we look at the results of this study, the numbers may be deceiving, but the percentage
is significant. After a severe TBI, 47.2% of female subjects as opposed to only 30.2% of male
subjects were able to return to their pre-trauma working level. This is the biggest difference in
the results, although it also is the most important one because the goal should be to return to pretrauma working levels. When we look at lower level functioning where subjects could still obtain
gainful employment although working at a lower level then pre-trauma levels, 31.9% of female
subjects ranked at a lower level as opposed to 43.1% of male subjects. Sheltered living (nongainful work) and unemployable levels were obviously not optimum recovery working levels.
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When comparing males to females in these two categories, 20.9% of females as opposed to 26.7
males were in sheltered living or unemployable post-trauma. These results suggest there may be
a correlation between TBI recovery and gender differences. Groswasser, Cohen, and Keren
(1998) note that at the time of discharge, biological factors play an important factor, while
psychosocial factors influence late outcomes. Groswasser, Cohen, and Keren (1998) also note
that there is a difference between the organization of brain functions between females and males
and this may also play a role in the outcome after a TBI, although this is unlikely due to the type
of injury. All subjects suffered blunt head trauma that lead to diffuse axonal injury. The
researchers did not do a detailed study of the focal lesions, but do to the large number of subjects
in this study, it is unlikely that this factor has played a role in the outcome (Groswasser, Cohen,
& Keren, 1998, p. 805-806).
What has been hypothesized in this study, and has been supported in other studies is well,
is the role progesterone in females plays in the recovery of TBI. Stein, Wright and Kellermann
(2008) conducted a literature review examining the possible neuroprotective properties of
progesterone, which would support the previous study by Groswasser, Cohen and Keren. To
think that progesterone has properties that may help someone recover from a TBI is not illogical.
Researchers have found that “administering relatively large doses of progesterone during the first
few hours to days after an injury significantly limits central nervous system (CNS) damage,
reduces loss of neural tissue, and improves functional recovery” (Stein, Wright, & Kellermann,
2008), p. 164). While our focus for the purpose of this paper is on TBI, it is important to note
that progesterone has been shown to possibly protect “from several forms of acute CNS injury,
including penetrating brain trauma, stroke, anoxic brain injury, and spinal cord injury (Stein,
Wright, & Kellermann, 2008, p. 164). Stein, Wright, and Kellermann (2008) hypothesize that

14

progesterone protects or rebuilds the blood-brain barrier, which in turn decreases the
development of cerebral edema, reducing inflammation, and it also may limit cellular necrosis
and apoptosis (Stein, Wright, & Kellermann, 2008, p. 164).
The researchers of this article summarize the cascading effect of brain trauma quite well
by stating that the tissue damage and destruction that accompanies the initial trauma put in
motion a deleterious process within the brain that can progressively enlarge the injured area,
leading to a lifetime of disability or even death. Changes, some of which are “pathosphysiologic
changes include release of excitatory amino acids, activation of the N-methyl-D-aspartate
receptor, the influx of toxic levels of calcium into neurons, activation of proinflammatory
cytokines, and other events” (Stein, Wright, & Kellermann, 2008, p. 164). Progesterone may
possibly block one or more of these cascading effects, therefore limiting or even preventing
further damage due to TBI. Previously there were only five treatments for TBI, which included
“hyperventilation, mannitol, cerebrospinal fluid drainage, barbiturates, and corticosteroids”
(Stein, Wright, & Kellermann, 2008, p. 165). None of these treatments helped as we did not see a
“decrease in morbidity or mortality after traumatic brain injury” (Stein, Wright, & Kellermann,
2008, p. 165). This is why promising results of progesterone are so important. The study does
note, that while not an optimum treatment for older patients, hypothermia has shown promising
results in some TBI subjects (Stein, Wright, & Kellermann, 2008). This as well is not unheard of
as we have seen promising results of hypothermia in spinal cord injury subjects (Dimar et al.,
2000).
Progesterone treatment has shown promise in both females and males while conducting
studies with rats. Stein, Wright, and Kellermann (2008) tested a control group of male and
female rats that were treated with peanut oil vehicle after injury, while another group of male and
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female rats were treated with progesterone after injury. When the brains of the subject rats were
examined 72 hours later, rats whom were treated with progesterone showed significantly less
cerebral edema than those rats treated with peanut oil vehicle. While limiting further injury is
important, the main goal after a TBI should be to improve function of the subject after injury.
Stein’s team studied four different categories of rats while conducting a Morris water maze,
which is a spatial navigation task. The groups of rats included head-trauma rats treated with
progesterone, head-trauma rats treated with a placebo, uninjured sham surgery controls with a
placebo, and uninjured sham surgery controls treated with progesterone. Several days later these
rats were tested in the Morris water maze, and it was found that the head-trauma rats treated with
progesterone performed the task significantly faster than placebo treated controls and nearly as
well as the sham surgery group (Stein, Wright, & Kellermann, 2008, p. 165-166).
A possible reason for these promising results in tests with progesterone, besides the
reduction of cerebral edema, is the “reduction of glutamate toxicity by decreasing the expression
and by up-regulating GABA” (Stein, Wright, & Kellermann, 2008, p. 166). Stein, Wright, and
Kellermann state that “GABA-mediated inhibition can decrease excessive injury-induced
excitotoxicity caused by the release of glutamate or other excitatory neurotransmitters” (Stein,
Wright, & Kellermann, 2008, p. 168). This is the opposite of corticosteroid treatment which has
been used in the past as “methylprednisolone treatment is deleterious in the setting of traumatic
brain injury” (Stein, Wright, & Kellermann, 2008, p. 166). The studies that show both male and
female rats benefit from progesterone after head trauma suggests that gender is not as much of a
factor as the hormone progesterone (Stein, Wright, & Kellermann, 2008).
While progesterone sounds like a miracle treatment for TBI’s, not everything is positive.
Stein, Wright and Kellermann cited the Women’s Health Initiative study. This study found that
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long-term hormonal replacement therapies such as estrogen and Provera (a synthetic
“progesterone-like” molecule) can increase a woman’s risk of stroke and heart disease. This
suggests looking at a risk analysis when considering progesterone treatment as a neuroprotectant.
The study does note that Provera administered with estrogen is a procoagulant. Secondly,
subjects in the Women’s Health Initiative study took both hormones over an extended period of
time, not short term, which would generally be the case when used to treat a TBI as a
neuroprotectant. Furthermore, Provera, or medroxyprogesterone acetate (MPA) “exhibits
different molecular and clinical properties from natural progesterone” (Stein, Wright, &
Kellermann, 2008, p. 169). Provera is a synthetic progestin, and “synthetic progestins in general
have different clinical properties and may not all be neuroprotective” (Stein, Wright, &
Kellermann, 2008, p. 169). Stein and his team found that while MPA does reduce cerebral
swelling after a TBI, it does not improve the functional outcome. Stein, Wright, and Kellermann
stated that MPA blocked estrogen-induced neuroprotection, as well as enhanced calcium toxicity
and failed to produce any beneficial effects (Stein, Wright, & Kellermann, 2008, p. 169).
The research on progesterone and the neuroprotective properties it has shown to possess
is so important because it has shown promise in rats, as well as the single human trial conducted
as of the date of Stein, Wright and Kellerman’s study (Stein, Wright, & Kellermann, 2008, p.
169). In the human trial conducted by Wright, Ritchie, Mullins, Kellermann, and Denson (2005),
the subjects received progesterone via continuous infusion intravenously. Control subjects
received a placebo. This study suggests the treatment is safe and there were no major differences
in regards to gender (Wright, Ritchie, Mullins, Kellermann, & Denson, 2005). While the results
were promising in this single human study, the sample pool was rather small with only 100
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subjects. This human trial does suggest that further investigation is warranted and should be
investigated (Stein, Wright, & Kellermann, 2008).
Do genetics play a role in recovery from a TBI?
We have explored age and gender, but do genetics play a role in TBI’s? Dardiotis et al.
(2010) found mounting evidence that suggests various genetic elements in the pathophysiology
of brain trauma. Dardiotis et al. (2010) goes on to suggest that the extent of brain injury after the
TBI may be modulated to some extent by genetic variants. Dardiotis’ study focuses on both
primary and secondary effects of TBI which is important because it is suggested that several
genes are factors in the pathophysiology of secondary brain damage. It is these secondary
processes that have been found to dramatically worsen the primary damage, which lead to a
cascade of axonal and neuronal pathologies. These cascading effects can determine the subject’s
overall clinical outcome after a TBI. Following the initial brain changes, we also will see
cellular, neurochemical, and molecular changes due to the TBI. These changes may include
“neuronal cell death, apoptosis, excitotoxicity, inflammatory infiltration, Aβ-peptide (Aβ)
deposition, disruption of calcium homeostasis, oxidative stress, and cytoskeletal and
mitochondrial sysfunction” (Dardiotis et al., 2010, p. 1). The deposition of Aβ is important
because of its role in diffuse plaques seen in the brains of those whom have suffered multiple
TBI’s and develop neurodegenerative diseases, including Alzheimer’s disease (AD) when
examining the brains of subjects post mortem (Lendon et al., 2003, p. 685).
The Apolipoprotein E (ApoE) is a “plasma lipoprotein implicated mainly in transporting
cholesterol and lipids throughout the tissues including the CNS” (Dardiotis et al., 2010, p. 2).
ApoE in the brain is “synthesized primarily by the astrocytes and the microglia plays a vital role
in maintenance of neuronal membranes, neuronal tissue repair, remodeling, and synaptogenesis”
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(Dardiotis et al., 2010, p. 2). It has been suggested that the ApoE4 allele, present after a TBI,
may increase the risk of a poor clinical outcome after the injury (Dardiotis et al., 2010, p. 2-6).
The ApoE4 allele is important because it is a risk factor for developing AD as well as a poorer
outcome after a TBI. After an acute TBI, we see a striking increase of intraneuronal ApoE. Due
to ApoE’s role in neural injury and repair, it is reasonable to think the increased levels of ApoE
after a TBI could affect long term recovery after the injury. As we will see later, there are strong
ties between those whom suffer multiple TBI’s, along with the presence of ApoE, and Aβ and
the relation to AD (Lendon et al., 2003, p. 683). Genetics plays a role in neurodegenerative
diseases as well, as do other factors such as TBI.
Neurodegenerative Disease
To understand what a neurodegenerative disease is, we must look at what a neuron is
first. JPND (Joint Programme – Neurodegenerative Disease) Research states “neurons are the
building blocks of the nervous system which includes the brain and spinal cord. Neurons
normally don’t reproduce or replace themselves, so when they become damaged or die they
cannot be replaced by the body” (JPND Research, 2015). Because “neurodegenerative disease is
an umbrella term for a range of conditions which primarily affect the neurons in the human
brain” (JPND Research, 2015) there is no one conclusive definition of what neurodegenerative
disease actually is. The Ontario Brain Institute published an information pamphlet on
neurodegeneration recently that described neurodegeneration as the “gradual deterioration in a
person’s cognitive abilities, such as memory. This loss is due to either structural changes that
prevent neurons (brain cells) from functioning normally, or to cell death. Neurodegeneration is a
key feature of several diseases that are referred to as “neurodegenerative diseases” (Ontario
Brain Institute, 2015). Some of these diseases or disorders include Multiple Sclerosis (MS),
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Myasthenia Gravis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrigs Disease), Alzhiemer’s
Disease (AD), Dementia, and cognitive disorders (Henry Ford Health System – Neuroscience
Institute), motor neuron diseases (MND), Parkinson’s Disease (PD) and PD-related disorders,
Huntington’s Disease (HD) (JPND Research, 2015) and Chronic Traumatic Encephalopathy
(CTE). For the purpose of this study I will focus on ALS, PD, AD and related dementia, and
CTE.
Amyotrophic Lateral Sclerosis (AS)
ALS is “an idiopathic, fatal neurodegenerative disease of the human motor system”
(Kiernan et al., 2011, p. 942). The New England Journal of Medicine states that “’Amyotrophic’
refers to the muscle atrophy, weakness, and fascination that signify disease of the lower motor
neurons. ‘Lateral sclerosis’ refers to the hardness to palpation of the lateral columns of the spinal
cord in autopsy specimens, where gliosis follows degeneration of the corticospinal tracts”
(Rowland & Shneider, 2001, p. 1688). While there have been different hypotheses on the cause
of ALS proposed over the years, ALS “remains poorly understood in terms of a unifying causal
hypothesis and indeed, might turn out to be a common end-stage phenotype of diverse causes”
(Mitchell & Borasio, 2007, p. 2033). Some of these proposed hypotheses for the cause of ALS
include occupational and environmental exposures, heavy-metal toxic effects, oxidant stress,
toxic stress and excitotoxicity (Mitchell & Borasio, 2007, p.2033). Currently, one of the focuses
of ALS research is excitotoxicity, which is “the process by which amino acid neuromodulators
such as glutamate become toxic when present at supraphysiological concentrations. Other
potential excitotoxins include AMPA and kainite” (Mitchell & Borasio, 2007, p. 2033). Still
other hypotheses have focused on protein aggregation, dysregulation of intracellular calcium,
and axonal transport defects (Mitchell & Borasio, 2007, p. 2034).
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Diagnosing ALS focuses on both upper and lower neuron degeneration with a set criteria
that needs to be met before a clinical diagnosis can be made.
“The diagnosis of ALS requires:
(A) the presence of:
(A:1) evidence of lower motor neuron (LMN) degeneration by clinical,
electrophysiological or neuropathologic evaluation.
(A:2) evidence of upper motor neuron (UMN) degeneration by clinical
examination, and
(A:3) progressive spread of symptoms or signs within a region or to other regions,
as determined by history or examination,
together with:
(B) the absence of
(B:1) electrophysiological or pathological evidence of other disease processes that
might explain the signs of LMN and/or UMN degeneration, and
(B:2) neuroimaging evidence of other disease processes that might explain the
observed clinical and electrophysiological signs” (Brooks, Miller, Swash, &
Munsat, 2000, p. 293).
Upon examination, a careful, thorough history as well as physical and neurological examination
“must search for clinical evidence of UMN and LMN signs in four regions (brainstem, cervical,
thoracic, or lumbosacral spinal cord) of the central nervous system (CNS)” (Brooks et al., 2000,
p. 293-294). There also are important features that, while present with other neurodegenerative
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diseases, will help to rule out a diagnosis of ALS or suggest the presence of another disease.
These include “plaques of multiple sclerosis and a focal cause of myelopathy” (Brooks et al.,
2000, p. 299).
Parkinson’s Disease (PD)
PD is another neurodegenerative disease that the Mayo Clinic describes as
“a progressive disorder of the nervous system that affects your movement. It develops
gradually, sometimes starting with a barely noticeable tremor in just one hand. But while
a tremor may be the most well-known sign of Parkinson's disease, the disorder also
commonly causes stiffness or slowing of movement. In the early stages of Parkinson's
disease, your face may show little or no expression or your arms may not swing when
you walk. Your speech may become soft or slurred. Parkinson's disease symptoms
worsen as your condition progresses over time” (www.mayoclinic.org, 2014).
While PD is the most widespread neurodegenerative movement disorder that we see in the aging
of the human nervous system, a conclusive diagnosis requires post mortem verification (Tredici,
Rub, De Vos, Bohl, & Braak, 2002, p. 413).
Much like we may see in AD, in PD we see “susceptible regions and vulnerable nerve
cell populations become progressively impaired owing to the extensive presence of Lewy
neurites and Lewy bodies” (Tredici et al., 2002, p. 413). Presently, there is no therapy that has
been proven to be neuroprotective or neurorestorative (Gupta, Dawson, & Dawson, 2008, p. 1),
but we do have promising leads when we search for causes of PD. Gupta, Dawson, and Dawson
state that “human postmortem material, animal models, and genetic analyses have provided
important clues to the etiology of PD. In particular, the genetic approach has recently unraveled a
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series of proteins that when mutated can cause familial forms of PD…this approach provides an
entry into identifying the signaling pathways that go errant during the development of PD.
Understanding these signaling pathways to neurodegeneration in PD will undoubtedly allow for
important access points for drug targeting” (Gupta, Dawson, & Dawson, 2008, p. 1-2). Another
possible cause of PD may be illegal drug use, and in particular those drugs that impact the
dopamine receptors in the brain. Cocaine is known as a drug that impacts the pleasure pathways
of the brain, or the dopamine receptors. We see dopamine replacement therapy (DRT), and the
dependence on DRT in many cases of PD. For example, in a study by Bearn, Evans, Kelleher,
Turner, and Lees, they note that “DRT is an established treatment for patients with PD” (Bearn,
Evans, Kelleher, Turner, & Lees, 2004, p.305). Giovannoni, O’Sullivan, Turner, Manson, and
Lees (2000) concur with this as they state “hedonistic homeostatic dysregulation is a
neuropsychological behavioral disorder associated with substance misuse and addiction. The
disorder has been recognized as a consequence of DRT in 15 patients with Parkinson’s disease”
(Giovannoni, O’Sullivan, Turner, Manson, & Lees, 2000, p. 423). The conclusion between
cocaine use and DRT is made by Bearn et al. (2004) where they found that “done-dependent
adverse effects of DRT include chorea and dystonia, mood swings and psychosis. Cocaine
induces motor stereotypies and reversible chorea through its effects on dorsal basal ganglia
dopaminergic systems. Depression, mood swings, paranoia, panic attacks and psychosis are
common complications of habitual cocaine use. Thus, both the clinical and neurochemical effects
of cocaine and amphetamine on dopaminergic neurotransmission are similar to those of DRT”
(Bearn et al., 2004, p. 306). This fact is made even clearer when one considers that “it is
hypothesized that chronic DRT may be complicated by a maladaptive pattern of dependent use in
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some patients with PD, the symptoms of which are analogous to those of cocaine dependence”
(Bearn et al., 2004, p. 306).
Alzheimer’s Disease (AD)
AD and related dementia are caused by “plaques… deposits of a protein fragment called
beta-amyloid (Aβ) that build up in the spaces between nerve cells. Tangles are twisted fibers of
another protein called tau that build up inside cells” (Alzheimer’s Association, 2015, p. 210).
Also present in the brains of patients with AD is “progressive dementia accompanied by neural
cell loss. The findings that mutations in the tau gene are responsible for frontal temporal
dementia proved that formation of neurofibrillary tangles has neurotoxic consequences”
(Rogaeva, 2002, p. 1). According to the Mayo Clinic, some symptoms of AD are
“troubles with memory, disorientation and misinterpretation of spatial relationships,
speaking and writing, thinking and reasoning, making judgments and decisions, planning
and performing familiar tasks, changes in personality and behavior which include
depression, anxiety, social withdrawal, mood swings, distrust in others, irritability and
aggressiveness, changes in sleeping habits, wandering, loss of inhibitions, and delusions”
(Mayo Clinic, 2014).
It is also important to consider that AD can be early onset in some cases. Rogaeva suggests that
early onset AD is genetic, linking the disease to “βAPP gene located on chromosome 21… ADassociated mutation in the βapp gene are clustered near the α-, β-, or γ-secretase cleavage sites,
demonstrating that they have a direct effect on βAPP processing” (Rogaeva, 2002, p. 2). Head
trauma in early adult life has been suspected to be associated with increased risk of AD and
dementia in late life. Plassman et al. (2000) found this to be true, as well as the more severe the
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injury, the greater the risk of developing AD and dementia later in life (Plassman et. al, 2000, p.
1163). This association remains the same for early onset AD, as “evidence from animal and
human experiments demonstrate links between TBI and the subsequent onset of premature,
psychiatric syndromes and neurodegenerative diseases, including AD and PD” (Kiraly & Kiraly,
2007, p. 1768).
Chronic Traumatic Encephalopathy (CTE)
Chronic Traumatic Encephalopathy, or CTE, was discovered by Dr. Bennett Omalu when
examining the brains of football players, in particular Mike Webster, in 2002 (Benet et. al, 2011,
p. 1). Dr. Omalu, as well as other researchers and the Brain Injury Research Institute, have
described and identified CTE in numerous contact sports athletes including football players,
boxers, professional wrestlers, and ice hockey players (Bennet et. al, 2011, p. 1). Gavett, Stern,
and McKee (2011) describe CTE as “a form of neurodegeneration that is believed to result from
repeated head injuries. Originally termed dementia pugilistica due to its association with
boxing… CTE has recently been found to occur following other causes of repeated head trauma,
suggesting that any repeated blows to the head, such as those that occur due to American
football, hockey, soccer, professional wrestling, and physical abuse, can also lead to
neurodegenerative changes” (Gavett, Stern & McKee, 2011, p. 1). Key amongst the pathological
changes in the brain are changes in cerebral atrophy, dense tau immunoreactive inclusions
(neurpfibrillary tangles, glial tangles, and neuropil neutrites), and diffuse axonal injury (Gavett,
Stern, & McKee, 2011, p. 1). There are also psychological changes which include “disordered
memory and executive functioning, behavioral and personality disturbances (e.g., apathy,
depression, irritability, impulsiveness, suicidality), parkinsonism, and occasionally, motor neuron
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disease. At the present time, there are no formal clinical or pathological diagnostic criteria for
CTE” (Gavett, Stern & McKee, 2011, p.1).
While CTE is associated with repeated concussions, “CTE is a neurodegenerative disease
that occurs years or decades following recovery from the acute or post-acute effects of head
trauma. The onset of CTE is often mid-life, usually after the athlete has retired from her or her
sport” (Gavett, Stern, & McKee, 2011, p. 2). Some of the earliest symptoms of CTE are
behavioral; “in particular, individuals with neuopathologically-documented CTE have been
described by family and friends as being more irritable, angry, apathetic, or having a shorter
fuse. Increased suicidality appears to be a particularly salient symptom caused by CTE” (Gavett,
Stern & McKee, 2011, p. 2). Cognitive abilities can also be affected by CTE, with some of the
first symptoms including poor executive functioning as well as diminished episodic memory
(Gavett, Stern, & McKee, 2011, p. 2). As the disease progresses, “movement (e.g.,
parkinsonism), speech, and ocular abnormalities may emerge in the context of declining
cognition and worsening comportment. A minority of cases with neuropathologicallydocumented CTE developed dementia before death; the relative infrequency of dementia in
individuals with CTE may be due in part to the fact that many individuals with CTE have either
committed suicide or died from accidents or drug overdose at an early age” (Gavett, Stern,
McKee, 2011, p. 3).
The correlation between TBI and neurodegenerative disease
There has been a link between TBI’s (both mTBI and TBI) in the past and
neurodegenerative diseases which I will show as we progress further. Some of these links are
controversial such as the case of PD, while others we see a definitive correlation such as in those
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afflicted with CTE. I will look at three neurodegenerative disorders in particular, those being PD,
AD, and CTE.
Parkinson’s Disease
While there has been much “interest in the potential relationship between TBI and
subsequent development of idiopathic PD, results from epidemiological studies have thus far
been mixed. In support of this proposed relationship, parkinsonism syndrome has been observed
after TBI, or as part of the clinical presentation of CTE” (Wong & Hazrati, 2013, p. 103). Even
though the “pathology of PD is well recognized, the mechanisms of neuronal death are uncertain.
Experimental studies have implicated oxygen free radicals and oxidative stress. α-Syn, which is
implicated in other neurodegenerative diseases such as AD, may play a role in development of
PD after TBI” (Masel & DeWitt, 2010, p. 1533). The key here may be α-Syn immunoreactivity,
as it is considered an important pathological finding in Lewy body dementia, multi-system
atrophy, and PD. When examining brain tissue samples from TBI patients, Masel and DeWitt
(2010) observed increased levels of α-syn (Masel & DeWitt, 2010, p. 1533).
Goldman et. al, (2006) found results that suggest “mild-to-moderate closed head injury
may increase PD risk decades later” (Goldman et. al, 2006, p. 65). Because previous studies have
shown to be inconsistent and the link between TBI and PD remains controversial, Goldman et. al
(2006) tried to limit independent variables that may affect the results of their study (Goldman et.
al, 2006, p. 65-67). The study does this by “testing the hypothesis that head injury increases PD
risk in twins discordant for PD. Twins are genetically identical or similar, which thereby controls
for the potential confounding effects of genetic factors. Also, twins’ environments are much
more similar than those of typical cases and control subjects, which thereby controls for many
confounding environmental factor, both recognized and unrecognized” (Goldman et. al, 2006, p.
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65). Goldman et. al, (2006) did find that, much like other neurodegenerative diseases, the more
TBI’s suffered by a patient, the higher the risk was for developing PD (Goldman et. al, 2006, p.
67).
Alzheimer’s Disease
We have seen a definitive link between AD and TBI’s, in particular early onset AD and
repetitive TBI’s. Sivanandam and Thakur’s (2012) study states that a TBI initiates a disease
process. To expand on this hypothesis, the study explains that “although many patients survive
the initial insult (injury), TBI initiates a chronic disease process that may ultimately contribute to
their deaths months to years later. Cell death after TBI is a major cause of neurological deficits
and mortality. TBI is a disease process with an initial injury that induces biochemical and
cellular changes which in turn contribute to continuing neuronal damage and death over time.
This continuing damage is known as secondary injury, and as a part of this process, multiple
apoptotic and inflammatory pathways are activated. The state of cerebral environment and
resultant secondary responses to TBI ultimately determine the final outcome” (Sivanandam &
Thakur, 2012, p. 1377). As stated previously, AD is caused by the buildup of Aβ proteins in the
brain. Sivanandam and Thakur (2012) point out that there are
“many pathological features common to both acute brain injury and AD, including Aβ
deposition, tau phosphorylation, neurite degeneration, synapse loss and microgliosis.
Neuroinflammatory responses may serve as a common denominator between these two
entities, and play a central role in mediating secondary neuronal injury in both chronic
neurodegenerative diseases and acute brain injury…. Although TBI is associated with
AD, the role played by TBI in the mechanism of disease development and progression is
not clearly understood. Primary feature of TBI is axonal damage and it is clear from
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many studies that axonal defect is a key disease manifestation of AD and responsible for
its symptoms” (Sivanandam & Thakur, 2012, p. 1377).
Furthermore, when looking at Aβ deposition and tau phosphorylation, we discover the “Amyloid
Cascade Hypothesis” suggested by Heuvel, Thornton, and Vink (2007). From a
neuropathological stance,
“AD is characterized by the presence of neurofibrillary tangles (NFTs) and neuritic
plaques. NFTs in the brain consist primarily of hyperphosphorylated tau. Neuritic
amyloid plaques consist primarily of aggregated amyloid-β peptides (Aβ), a peptide of
40-42 amino acids, which are surrounded by dystrophic neurites, microglia and
retroactive astrocytes. It is now generally accepted that the development of these two
pathologies is central to the pathogenesis of AD and the leading ‘amyloid cascade
hypothesis’ suggests that it is the accumulation of Aβ in the brain which is the primary
influence in AD. Aβ has been hypothesized to cause the pathologic and behavioral
manifestations of AD, including neurofibrillary tangle formation, neuronal degeneration,
synaptic dysfunction and loss as well as impaired memory. According to this theory, the
accompanying NFT formation and neuronal loss are downstream events resulting from an
imbalance between Aβ production from its precursor Amyloid Precursor Protein (APP)”
(Van Den Heuvel, Thornton, & Vink, 2007, p. 304).
A relationship has been suggested between “TBI and AD since TBI leads to overexpression of
APP within neuronal cell bodies and accumulation of APP within traumatically injured axons.
Theoretically, the accumulation of APP results in an increase in the substrate that could
potentially be processed to form amyloidogenic Aβ. It has therefore been hypothesized by a
number of groups that the overexpression of APP may exceed the limit of normal processing
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capacity, resulting in mismetabolization of APP into potentially amyloidogenic fragments” (Van
Den Heuval, Thornton, & Vink, 2007, p. 306).
The evidence of a correlation between TBI and early onset AD is due to a case report
documenting a 38-year old man who previously suffered a single severe TBI. Since then,
numerous studies of the brains of boxers suffering from CTE (dementia pugilistica) have also
demonstrated AD-like pathology with diffuse Aβ plaque deposition. It is fair to speculate that
such Aβ deposition resulted from repeated blows to the head over a long period of time. It also is
fair to speculate that such events may also occur in the brains of others whom have suffered
repetitive head trauma (Van Den Heuval, Thornton, & Vink, 2007, p. 307). Van Den Heuval,
Thornton, and Vink (2007) state that “histopathological studies of such individuals who died
after suffering a single severe TBI demonstrate widespread cerebral Aβ deposition in short and
long term survivors irrespective of age” (Van Den Heuval, Thornton, & Vink, 2007, p. 307). Van
Den Heuval, Thornton, & Vink (2007) do make note that there are discrepancies in these
findings as in other studies very few, and in some instances, no subjects showed any evidence of
Aβ plaques.
Chronic Traumatic Encephalopathy
Where we have seen suggestions of a correlation between neurodegenerative disease and
TBIs, when we look at CTE there is a wealth of evidence that supports this correlation. Omalu,
Hamilton, Kamboh, DeKosky, and Bailes (2010) state that “CTE represents the cumulative, long
term neurologic consequences of repetitive concussive and subconcussive blows to the brain”
(Omalu, Hamilton, Kamboh, DeKosky, & Bailes, 2010, p. 40). It is important to note that,
possibly because CTE is a relatively new disease discovered in 2002 by Dr. Bennett Omalu, risk
factors for CTE other than repetitive brain trauma may exist and are unknown at this time
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(Baugh et al., 2012, p. 244). McKee et al. (2013) mention four symptomatic stages in regards to
CTE. The symptoms of “stage I CTE include headache and loss of attention and concentration.
Additional symptoms in stage II included depression, explosivity, and short term memory loss.
In stage III, executive dysfunction and cognitive impairment were found, and in stage IV,
dementia, word finding difficulty and aggression were characteristic” (McKee et al., 2013, p. 4344). These symptoms typically do not present themselves until “8-10 years after experiencing
repetitive mild traumatic brain injury” (McKee et al., 2013, p. 44). This study also notes that
“there is an ordered and predictable progression of hyperphosphorylated tau abnormalities
through the nervous system in CTE that occurs in conjunction with widespread axonal disruption
and loss. The frequent association of CTE with other neurodegenerative disorders suggests that
repetitive brain trauma and hyperphosphorylated tau protein deposition promote the
accumulation of other abnormally aggregated proteins including TAR DNA-binding protein 43,
amyloid beta protein and alpha-synuclein” (McKee et al., 2013, p. 44). There are some
similarities between AD and CTE, and to help distinguish between the two, I included Table 1
which was published in McKee et al., (2013).
Current and future advances in treating TBIs and neurodegenerative disease
While we have medications and certain psychotherapy techniques to relieve some
symptoms of the effects of TBI and neurodegenerative disease, in particular depression, anxiety
and headaches, the scientific community is searching for possible ways to cure or stop the
progression of neurodegenerative disease. As seen below, progress is being made but we are not
quite to the point we need to be yet.
It seems that as a society we feel there is or should be a drug for everything.
Unfortunately with neurodegenerative diseases, that is not always the case. Modi, Pillay, and
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Choonara (2010) stated that “due to limitations posed by the restrictive blood-brain barrier
(BBB), conventional drug delivery systems do not provide adequate cyto-architecture restoration
and connection patterns that are essential for functional recovery in neurodegenerative
disorders(NDs)” (Modi, Pillay, & Choonara, 2010, p. 154). This is the reason why I will focus
less on pharmaceutical options and place more emphasis on alternative treatments.
Nanotechnology
A recent advancement in treating neurodegenerative disease utilizes nanoparticles. Due to
their small size, “nanotechnology employs engineered materials or devices that interact with
biological systems at a molecular level and could revolutionize the treatment of NDs by
stimulating, responding to, and interacting with target sides to induce physiological responses
while minimizing side effects” (Modi, Pillay, & Choonara, 2010, p. 154). Fernandes, Soni, and
Patravale (2010) concur with this hypothesis. The blood brain barrier is unique in that “unlike
peripheral capillaries that allow relatively free exchange of substances across/between blood and
tissue parenchyma, the BBB strictly limits transport into the brain through both physical (tight
junctions) and metabolic (enzymes) barriers” (Fernandes, Soni, & Patravale, 2010, p. 167).
Lipid-based nanoparticles and polymeric nanoparticles are the two existing nanoparticulate
system categories (Fernandes, Soni,& Patravale, 2010, p. 173). It also is important to note that
the “lack of toxicology data on nanocarrier systems hinders governmental regulation. Currently,
no regulatory requirement to test nanoparticles for health, safety, and environmental impacts has
been formalized. Toxicity studies are critical to establish the full in vivo potential of
nanotechnology and nanomedicine in particular. Understanding the physiochemical, molecular,
and physiological processes of nanoparticles is imperative for nanomedicine to become a reliable
and sustainable treatment modality” (Fernandes, Soni, & Patravale, 2010, p. 175).
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Medical Marijuana (CBDs)
Although controversial, marijuana has proven beneficial in the treatment of
neurodegenerative diseases. The focus of the medicinal use of marijuana is on cannabidiol
(CBD), which lacks any psychotropic effect usually associated with marijuana (Iuvone, Esposito,
De Filippis, Scuderi, & Steardo, 2009, p. 65). There are three different groups of cannabinoids
(CDs), with CBD being extracted from phytocannabinoids (Iuvone, Esposito, De Filippis,
Scuderi, & Steardo, 2009, p. 66). There are “two membrane receptors for CBs, both coupled to
G1 protein, and named CB1 and CB2 have been identified so far. … it has been reported that CB1
agonism was able to prevent tau hyperphosphorylation in cultured neurons and antagonize
cellular changes and behavioral consequences in β-anyloid-induced rodents” (Iuvone, Esposito,
De Filippis, Scuderi, & Steardo, 2009, p. 66). Both CB1 and CB2 protective roles have “been
recognized not only in AD models but also in other experimental paradigms of
neurodegenerative disorders” (Iuvone, Esposito, De Filippis, Scuderi, & Steardo, 2009, p. 67).
There is “growing evidence that CB1, and possibly CB2, receptor interactions could affect
neuropathology and disease progression in rodent model of both MS and ALS” (Iuvone,
Esposito, De Filippis, Scuderi, & Steardo, 2009, p. 67). CBD has been shown to have therapeutic
properties in experiments in regards to anxiolytic, anticonvulsant, anti-oxidant, anti-emetic, antiinflammatory, and antipsychotic agent. This makes CBDs a potential medicine for the treatment
of oxidative injury, epilepsy, neuroinflammation, anxiety, schizophrenia, vomiting, and nausea
(Fernàndez-Rulz et al., 2012, p. 1). Due to CBDs anti-inflammatory and anti-oxidant properties,
“the neuroprotective potential of CBD is of particular interest and is presently under intense
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preclinical research in numerous neurodegenerative disorders” (Fernàndez-Rulz et al., 2012, p.
1).
While only three years apart, it is important to note a key difference between these
studies. While Iuvone, Esposito, De Filippis, Scuderi, and Steardo (2009) place emphasis on
CB1, Fernàndez-Rulz et al., (2012) instead states that CB1 is not activated. So as we can see,
therapeutic use of CBD is an evolving field. This could be in part due to research into
endocannabinoids, which “differ in chemical structure from phytocannabinoids. Among the
endocannabinoids so far identified are anandamide (N-arachidonoylethanolamide, AEA), 2arachidonoylglycerol (2-AG), 2-arachidonoylglycerol ether (noladin ether), O-arachidonoylethanolamine (virodhamine), and N-arachidonoyl-dopamine (NADA). The first two discovered
endocannabinoids, anandamide and 2-AG, have been most studied” (Grotenhermen, 2006, p. 3).
Tanveer, McGuinness, Daniel, Gowran, and Campbell (2012) created a flow chart (Figure 2) that
shows a good representation of how CBDs can have medicinal benefits to those suffering from
neurodegenerative disease. Because AD is a neurodegenerative disease that has an inflammatory
component, “the endocannabinoid system has attracted interest as a novel target for AD, as well
as other neurodegenerative disorders, due to the potential neuroprotective, anti-inflammatory,
and neurotrophic properties of cannabinoid compounds” (Tanveer, McGuinness, Daniel, Gowran
& Campbell, 2012, p. 633-634). Due to psychological effects of neurodegenerative diseases, it is
important to note that use of CBDs may reduce anxiety as well as can be used as an antipsychotic
agent as stated above. Tanveer, McGuinness, Daniel, Gowran, and Campbell (2012) also note
that cannabinoid-based medications may assist in the treatment and management of behavioral
symptoms of some neurodegenerative diseases (Tanveer, McGuinness, Daniel, Gowran, &
Campbell, 2012, p. 634).
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Stem Cell Treatment
Yet another controversial method for treating neurodegenerative disease might be stem
cell treatments. Lindvall, Kokaia, and Martinez-Serrano (2004) state that “recent progress shows
that neurons suitable for transplantation can be generated from stem cells in culture, and that the
adult brain produces new neurons from its own stem cells in response to injury” (Lindvall,
Kokaia, & Martinez-Serranao, 2004, p. S42). While studying animals, it was “demonstrated that
neuronal replacement and partial reconstruction of damaged neuronal circuitry is possible. There
is also evidence from clinical trials that cell replacement in the diseased human brain can lead to
symptomatic relief “(Lindvall, Kokaia, & Martiniez-Serrano, 2004, p. S42). It is important to
recognize that in each neurodegenerative disease, “a different spectrum of cell types is affected;
therefore, different types of neurons are required for replacement” (Lindvall, Kokaia, &
Martiniez-Serrano, 2004, p.S42). Thus far, “the research has advanced furthest in diseases of the
basal ganglia, namely Parkinson’s disease, and Huntington’s disease, and of these two conditions
the development of stem cells as a donor source has advanced furthest for Parkinson’s disease.
However, a variety of other neurodegeneration conditions, including ALS, Alzheimer’s disease,
and demyelinating diseases such as MS are potential targets for circuit repair” (Rosser, Zietlow,
& Dunnett, 2007, p. 689). In order for stem cells to repair neuronal circuits, “donor cells must be
able to integrate into the damaged host tissue and make synapses with host neurons. A major
requirement in achieving circuit repair is to persuade potential donor cells to adopt the precise
neural phenotype of the cells lost to the disease process… there is a considerable body of work
that demonstrate that this is an absolute requirement for recovery of function” (Rosser, Zietlow,
& Dunnett, 2007, p. 689).
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Ultrasound Treatment
As mentioned previously, one of the largest hurdles to treatment of neurodegenerative
diseases has been the blood brain barrier and the protective properties of this barrier.
Furthermore, a key component in neurodegenerative disease is amyloid-β proteins, tau protiens,
and neurofibrillary tangles. Jordȁo et al., (2013) utilized a noninvasive technique that “targeted
drug delivery to the brain… using transcranial focused ultrasound (FUS), which transiently
increases permeability of the blood-brain barrier (BBB) for localized delivery of therapeutics
from the blood to the brain” (Jordȁo et al., 2013, p. 1). In addition to permeating the BBB, Jordȁo
et al., (2013) also found that “FUS can deliver intravenously-administered antibodies to the brain
of a mouse model of AD and rapidly reduce plaques composed of amyloid-β peptides (Aβ). …
We demonstrate that transcranial FUS application leads to a significant reduction in plaque
burden four days after a single treatment in the TgCRND8 mouse model of AD and that
endogenous antibodies are found bound to Aβ plaques” (Jordȁo et al., 2013, p. 1). This is
important due to the role that plaques play in neurodegenerative diseases.
The importance of amyloid-β plaques cannot be understated, and a non-pharmacological
approach to reducing these plaques could prove very beneficial to those suffering from
neurodegenerative disease in the future. Recently it was found that ultrasound may show promise
in reducing the Aβ and possibly restore memory in those affected by AD. Leinenga and Götz
(2015) presented a “non-pharmacological approach for removing Aβ and restoring memory
function in a mouse model of AD in which Aβ is deposited in the brain. We used repeated
scanning ultrasound (SUS) treatments of the mouse brain to remove Aβ, without the need for any
additional therapeutic agent such as anti-Aβ antibody. … Plaque burden was reduced in SUStreated AD mice compared to sham-treated animals, and cleared plaques were observed in 75%
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of SUS-treated mice” (Leinenga & Götz, 2015, p. 1). Mice that were tested “displayed improved
performance on three memory tasks: the Y-maze, the novel object recognition test, and the active
place avoidance task” (Leinenga & Götz, 2015, p. 1). Previously, “only one method has been
demonstrated to open the BBB noninvasively and repeatedly, that is, nonthermal focused
ultrasound coupled with intravenous injection of microbubbles, which are used as ultrasound
contrast agents” (Leinenga & Götz, 2015, p. 1). Tau protein does play a role because
“microtubule-associated protein tau becomes phosphorylated in response to Aβ. … but
phosphorylation was too variable to reveal a difference between groups” (Leinenga & Götz,
2015, p. 6). As noted previously, inflammation is also an important factor in neurodegenerative
diseases. Leinenga and Götz (2015) determined “no difference between SUS-treated and shamtreated APP23 mice” (Leinenga & Götz, 2015, p. 6) in regards to “SUS up-regulated
inflammatory markers associated with tissue damage” (Leinenga & Götz, 2015, p. 6). While
SUS shows promise, Leinenga and Götz (2015) do point out that “SUS treatment engages
microglia and promoted internalization of Aβ into microglial lysosomes, thereby reducing Aβ
and plaque load in the APP23 transgenic mouse model of AD as well as restoring function in
tests of spatial and recognition memory. Although we have shown that SUS treatment induces
microglial to effectively clear Aβ, it is equally possible that ultrasound and the transient opening
of the BBB also attenuates the deposition of newly generated Aβ” (Leinenga & Götz, 2015, p. 7).
It is important to note that Leinenga and Götz (2015) stated they did not address this in the study.
Prevention and education of TBIs
There is an abundance of information lending to the hypothesis that repetitive TBI’s can
contribute to the development of neurodegenerative diseases, in particular PD, AD, and CTE.
Furthermore it has been shown that there may be a correlation between early onset AD and
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repetitive TBI’s. So it would stand to reason that prevention and education about TBI’s would be
a good step in preventing neurodegenerative diseases.
Prevention of TBI’s
The majority of TBI’s can be prevented as they occur in contact sports. There is
some difficulty estimating the instances of TBI’s in the US, as the amount of TBI’s suffered
range from “300,000 to 3.8 million annually” (Wiebe, Comstock, & Nance, 2011, p. 69). Due to
the frequency of TBI’s in contact sports, often children are the ones who are injured (Wiebe,
Comstock, & Nance, 2011, p. 69). Benson et al., (2013) suggested that there was no conclusive
evidence to support that equipment such as headgear or mouth guards prevent TBI’s in contact
sports, nor does increasing neck strength (Benson et al., 2013, p. 1). When looking at neck
strength, this may conflict with the suggestion of Meehan, Taylor and Proctor (2011) that the
weaker neck muscles and larger head may play an important role in sustaining a TBI (Meehan,
Taylor, & Proctor, 2011, p. 2). When considering headgear and mouth guards, we can see the
importance when looking at sports such as bicycling, skiing, and snowboarding, where evidence
supports the use of headgear may reduce the risk of a head or brain injury. It is important to note
that the use of helmets in football and ice hockey do play a role in preventing severe TBI’s as
well as skull fractures (Benson et al., 2013, p. 5). Benson et al., did conclude that two of the
biggest factors in preventing head trauma are to eliminate body checking in ice hockey with
players between 11-12 years of age, as well as implementing an annual awareness program for
coaches and referees (Benson et al., 2013, p. 5). The most efficient way to reduce TBI’s appears
to be further rule changes in contact sports as well as targeted training to reduce impacts to the
head while playing sports (Crisco & Greenwald, 2011, p. 2). Crisco and Greenwald (2011)
correlated the impact exposure and impact severity and hypothesized “that reducing or limiting
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the number and severity of head impacts would result in a decrease in the incidence and severity
of clinically relevant cognitive deficits and in the incidence of clinical diagnosis of concussion”
(Crisco & Greenwald, 2011, p. 2). To do this, rules of many sports have had to be modified. One
of the largest changes suggested would be to eliminate intentional contact with the head in
sports, as well as changes in tackling, blocking and checking techniques. Both the NFL and the
NHL have adopted rule changes intended to eliminate intentional blows to the head (Crisco &
Greenwald, 2011, p. 2). World Wrestling Entertainment (WWE) has also made changes to how
their entertainers perform in the ring. WWE donated 1.2 million dollars to The Sports Legacy
Institute to further research into developing treatment of CTE. WWE has also eliminated certain
moves such as unprotected steel chair shots to the head in hopes of preventing concussions. As
of 2006, the WWE also implemented baseline neuropsychology tests for all of their performers,
something that is very similar to what the NFL has implemented (Michoces, 2013, p. 1). All of
this ties into education about how to recognize and treat TBI’s.
Education about TBI’s
As noted by Cisco and Greenwald (2011), rule changes in ice hockey for children has
been shown to reduce the incidents of TBI’s. It therefore stands to reason that early education
may be the best key in TBI awareness and prevention. Tator (2012) mentions the five “Es” are
essential to prevention of concussion. These five “Es” to prevent injury “include epidemiology,
education, engineering, enforcement/legislation of rules, and evaluation of injury prevention
programs” (Tator, 2012, p. 293). In support of the argument for more education on TBI’s is the
fact that many people still believe one needs to lose consciousness to suffer a TBI, when in fact
the majority of TBI’s suffered occur without any loss of consciousness (Tator, 2012, p. 294).
When developing strategies and resources to educate and increase awareness of TBI’s, Tator
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(2012) suggests that while “approximately 90% of the content is uniform, it is suggested that
such information be as sport-specific as possible” (Tator, 2012, p. 295). Some of the ideas that
Tator (2012) suggests include TBI road shows, TBI education and awareness committees,
concussion cards to help determine if a TBI has been suffered and guidelines for return to play,
websites, mandatory TBI education, preseason sports team meetings on TBI education, journal
articles/continuing education/webinars, and locker room posters. A great example of the use of
locker room posters would be the NFL. In 2010 the league initiated a campaign via locker room
posters urging players to report TBI’s to team officials (Tator, 2012, p. 296). Tator (2012)
suggests a three pronged strategy of primary, secondary and tertiary strategies to prevent TBI’s.
Initially, “primary strategies are those that prevent concussions from happening. …Secondary
prevention refers to expert management of a concussion that has already occurred; such
strategies are designed to prevent worsening, such as that which occurs most dramatically with
second impact syndrome. Tertiary strategies help prevent the long-term complications of
concussion, such as chronic traumatic encephalopathy (CTE) by advising the participant to
permanently discontinue play based on evidence-based guidelines” (Tator, 2012, p. 297).
As mentioned previously, early education is key to TBI prevention. With this in mind, the
Centers for Disease Control and Prevention (CDC) partnered with experts in the field of head
trauma and developed a tool kit that was sent out to high school coaches. This tool kit contained
practical and easy to use TBI related information, with the intent of reducing the number of
sports related TBI’s (Sarmiento, Mitchko, Klein, & Wong, 2010, p. 112). The tool kit included
“a guide for coaches, a video, clipboard sticker, wallet card, and fact sheets for parents and
athletes. The combined promotional efforts of the CDC, partners, and expert panel members,
resulted in more than 20,000 tool kits distributed nationwide within 3 months of its launch”
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(Sarmiento et a;., 2010, p. 113). The tool kit materials were also made available free of charge on
the CDC’s website (Sarmiento et al., 2010, p. 113). The focus of Sarmiento et al., (2010) study
was quite simply, did this tool kit obtain the desired results and how well did this tool kit work to
reduce the instances of TBI amongst athletes. The majority of coaches did feel that the
information provided by the CDC tool kit was more comprehensive than current policies in place
at their schools, but there were barriers to education and TBI management that were mentioned.
Some of these barriers include parents’ and/or athletes’ competitiveness, underestimating the
potential risks of concussions, lack of health insurance, and viewing injuries as a sign of
weakness. Sarmiento et al., (2010) makes note that one of the biggest barriers has been parents
and their reluctance to take an injury seriously unless their child is bleeding profusely or a bone
is broken (Sarmiento et al., 2010, p. 115). One of the most important results of the distribution of
this tool kit was the fact that “half of survey respondents (50%) reported that the tool kit changed
their views on the seriousness of concussions. Of those coaches who noted a change, all of them
reported that they now regard concussions more seriously” (Sarmiento et al., 2010, p. 115). An
important aspect covered by Sarmiento et al., (2010) is the subject of rest and limiting activities
during the recovery period of a TBI. Even activities that may not be physically demanding such
as studying, playing video games or working on the computer may cause TBI symptoms to
reappear or worsen. Sarmiento et al., (2010) also mentions what is called cognitive exertional
effects, which is seen when TBI symptoms worsen when doing schoolwork. Thinking and
learning, both cognitive activities, “must be carefully monitored and managed to prevent this
from happening. Students who return to school after a concussion may need to take rest breaks as
needed, spend fewer hours at school, be given more time to take tests or complete assignments,
receive help with school work, and reduce time spent on the computer, reading, or writing”
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(Sarmiento et al., 2010, p. 117). It also is very important not to return to any physical activity
until the athlete is symptom free and medically cleared (Sarmiento et al., 2010, p. 117). The
reason this is so important is the fact that this is an important step to avoid second impact
syndrome. Something else that is very important is speaking with the athlete about the effects of
a TBI, what the athlete may experience emotionally and physically and offer encouragement and
support during this time (Sarmiento et al., 2010, p. 117).
Conclusion
As we have seen, neurodegenerative diseases/disorders are a wide umbrella. My focus
was primarily on head trauma as the cause, but it has been hypothesized that genetics may play a
role as well. Regardless of the cause, there is no doubt that neurodegenerative diseases are
debilitating and take a toll not only on the person suffering from the disease but also their family
and friends. I did focus on Parkinson’s disease (PD), Alzheimer’s disease (AD) which is usually
associated with progressive dementia, and Chronic Traumatic Encephalopathy (CTE) because
these three diseases have been linked to traumatic brain injury (TBI) in a number of studies.
Presently there is no way to conclusively determine if someone is suffering from one of these
diseases until a post mortem examination of the brain is conducted, although there are symptoms
common to these diseases where we may see an indication of what to expect upon examination.
When a TBI occurs, a cascading set of events results in glutamate toxicity, beta-amyloid (Aβ)
protein plaque buildup and neurofibrillary tangles of tau protein buildup within the cells. As
these elements build up in the brain, neurons degenerate and die.
There are new treatments on the horizon that may treat the symptoms, and in some cases
possibly break up the Aβ protein plaques. My goal was to focus on alternative or new treatment
methods such as nanotechnology, medicinal marijuana, stem cell research and ultrasound
42

treatment. The most controversial in the United States would be medicinal marijuana and stem
cell treatments due to government regulation and ethical complications, but I believe with time
we will see the potential of these ground breaking methods opening up the doors to more
research. More recently we have seen promise in repeated scanning ultrasound (SUS) where
when used on mice, SUS broke up the Aβ plaques and a majority of the mice regained memory
that was previously lost due to AD symptoms. While the focus was mice with symptoms of AD,
AD and CTE are closely linked in a number of ways, so this method may show promise with
other neurodegenerative diseases as well.
Possibly the most important tool we have in the fight against neurodegenerative disease
and TBI is education and prevention. We have already seen major strides made in both of these
areas, but we do still have a long way to go. Major sports leagues and promotions have taken the
lead not only in donating money to research, but also in prevention of TBI’s by changing the
rules of their respective sports. We have seen the implementation of neuropsychology tests,
reporting of TBI’s, education of the short term and long term effects of a TBI, and why it is so
important to not continue to compete while suffering the symptoms of a TBI in sports leagues
such as the NFL, NHL, and WWE amongst others. But is this enough? The CDC distributed a
“Heads Up” tool kit to high school coaches to help educate coaches, players and their parents of
the effects of TBI’s, and we have seen some success, although there are barriers that we must
overcome. We will always see athletes who do not want to take themselves out of the game.
Athletes by nature are competitive and often times stubborn and rarely will pull themselves from
competition, so this barrier is not unexpected. Surprisingly though, one of the barriers to
preventing TBI’s in young athletes are parents that do not take TBI’s as seriously as they should.
When one considers the possible link between repetitive TBI’s being linked to early onset AD
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and dementia as well as CTE, and the impact these diseases have on the families of the athletes
suffering from these diseases, it is evident that while we have made great strides in education and
prevention of TBI, there still is progress that can be made.
For a long time, those whom suffered the effects of TBI’s and later developed a
neurodegenerative disease suffered in silence. No one wanted to admit they suffered from
anxiety. No one wanted to admit they suffered from depression. People knew something was
wrong, but didn’t know what it was. They couldn’t sleep properly, suffered headaches regularly,
suffered memory loss as well as deficits in other cognitive abilities and other various symptoms.
It was only recently that we now know why and we can at least provide some relief to those
suffering if they ask for help. We are now seeing people asking for help, which that in itself is an
improvement. So while we have come a long way in the field of neurodegenerative disease and
head trauma, we do still have a long way to go.
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Abstract
Figure 1. (McKee et al., 2013, p. 46)
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Figure 2. (Tanveer, McGuinness, Daniel, Gowran, & Campbell, 2012, p. 634)
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